Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018.

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

Pasadena. CA | Posted on November 27th, 2018

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 6744427.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 6744427.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 5, 2019 January 18th, 2019

ULVAC Inc., and Oxford Instruments Plasma Technology collaborate to bring Atomic Scale Processing solutions to the Japanese Power and RF markets January 18th, 2019

Kiel physicists discover new effect in the interaction of plasmas with solids January 18th, 2019

Brilliant glow of paint-on semiconductors comes from ornate quantum physics January 18th, 2019

Nanomedicine

Nanobiotix Plans to Conduct Registered Public Offering in the United States January 17th, 2019

Chirality in 'real-time' January 14th, 2019

Ultra-sensitive sensor with gold nanoparticle array January 9th, 2019

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases January 7th, 2019

Announcements

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 5, 2019 January 18th, 2019

ULVAC Inc., and Oxford Instruments Plasma Technology collaborate to bring Atomic Scale Processing solutions to the Japanese Power and RF markets January 18th, 2019

Kiel physicists discover new effect in the interaction of plasmas with solids January 18th, 2019

Brilliant glow of paint-on semiconductors comes from ornate quantum physics January 18th, 2019

Financial Reports

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 5, 2019 January 18th, 2019

180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018 October 29th, 2018

180 Degree Capital Corp. to Report Third Quarter 2018 Financial Results on Monday, October 29, 2018 and to Host a Conference Call on Tuesday, October 30, 2018 October 24th, 2018

Nanometrics to Announce Third Quarter Financial Results on October 30, 2018 October 10th, 2018

Events/Classes

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 5, 2019 January 18th, 2019

Media invited to open meeting on the future of quantum technology held at RIT Jan. 23-25: Leaders from NASA, NSF, NIST and Sandia National Laboratory to attend January 11th, 2019

Nanometrics to Participate in the 21st Annual Needham Growth Conference January 7th, 2019

CEA-Leti’s RRAM-based TCAM Circuits Meet Requirements of Multicore Neuromorphic Processors December 5th, 2018

Nanobiotechnology

Using bacteria to create a water filter that kills bacteria: New technology can clean water twice as fast as commercially available ultrafiltration membranes January 18th, 2019

Nanobiotix Plans to Conduct Registered Public Offering in the United States January 17th, 2019

Cartilage could be key to safe 'structural batteries' January 11th, 2019

Ultra-sensitive sensor with gold nanoparticle array January 9th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project